Scimed v. ACS
This article was originally published in The Gray Sheet
Executive SummaryLilly subsidiary Advanced Cardiovascular Systems' motion to stay litigation filed by Scimed is granted by U.S. District Court for the Northern District of California. Litigation proceedings in the case are postponed indefinitely, according to ACS. Scimed had filed suit May 31, alleging that ACS' Flowtrack 40 and Rx Elipse percutaneous transluminal coronary angioplasty catheters infringe two of its patents ("The Gray Sheet" June 6, In Brief). ACS' motion to stay argued that a settlement agreement reached between the two companies in August 1991 applied to this case. The settlement, according to ACS, included an arbitration provision and a covenant not to sue
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.